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Abstract
Background: Dioxins and dioxin-like compounds have half-lives typically between 7.2 years and 15 years. Our
previous study of patients poisoned by extremely high concentrations of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF)
in the ‘Yusho incident’ in 1968 found that in some the half-life of blood 2,3,4,7,8-PeCDF tended towards infinity.
This suggests that there are two groups of Yusho patients, those with 2,3,4,7,8-PeCDF half-lives around 10 years,
and those with half-lives near infinity. We sought to establish the proportions of each in a cohort of 395 Yusho
patients, and whether the proportions were changing over time.
Methods: We undertook longitudinal measurement of the blood concentration of 2,3,4,7,8-PeCDF in our cohort
between 2002 and 2010. We estimated the change in concentration for each patient using linear regression for
measured 2,3,4,7,8-PeCDF concentration, then compared the distribution of changes in concentrations with our
previous study.
Results: In patients in whom the blood concentration of 2,3,4,7,8-PeCDF exceeded 50 pg/g lipid, the proportion
8.0 % of patients exhibiting half-lives less than 13.3 years fell compared with our previous study (28.2 %), while the
proportion with near infinity half-lives increased.
Conclusion: The prolongation of the half-lives was likely a consequence of age-related factors.
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Introduction
The ‘Yusho incident’ was an episode of food poisoning
that occurred in western Japan in 1968. Initial reports
indicated that Yusho was caused by polychlorinated bi-
phenyls (PCBs). However, following a number of studies,
it is now considered that 2,3,4,7,8-pentachlorodibenzo-
furan (PeCDF) was the main causative compound of
Yusho [4, 19]. The concentrations of dioxins and dioxin-
like compounds in the blood of Yusho patients have
been measured at annual medical checkups since 2001
[8, 18].
Once ingested, dioxins and dioxin-like compounds
are excreted extremely slowly, but given the health
implications there has been a great deal of interest in the
half-lives of these compounds in humans. In patients with
high blood concentrations of dioxin-like compounds, half-
lives of 1.1 years have been reported, increasing to 7.2 years
in patients with low concentrations [9]. Other estimates of
dioxin-like compound half-lives include 8.9 years by
Masuda et al. [10], 9.6 years by Ryan et al. [15], and
9.1 years by Iida et al. [6]. Many researchers have reported
half-lives of PCBs to be less than 10 or 15 years [14, 16].
We previously examined the half-lives of 2,3,4,7,8-PeCDF,
which we consecutively measured from 2001 to 2006 in
326 Yusho patients [11]. Notably, among patients with
2,3,4,7,8-PeCDF blood concentrations in excess of 50 pg/g
lipid or higher, we identified two groups—one showing a
half-life of around 10 years and the other showing no re-
duction in 2,3,4,7,8-PeCDF levels over time. This suggests
that the latter group of patients maintained high blood
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levels of 2,3,4,7,8-PeCDF [11]. Since the blood concentra-
tions of 2,3,4,7,8-PeCDF in the two groups are three or
more times higher than the general public, it seems un-
likely that the extended half-lives can be explained by in-
gestion from food [2, 11]. We re-examined the distribution
of the half-lives of 2,3,4,7,8-PeCDF in 395 Yusho patients
between 2002 and 2010.
Materials and methods
The subjects were 395 patients whose blood concentra-
tions of 2,3,4,7,8-PeCDF had been measured three or
more times at annual Yusho medical checkups between
2002 and 2010, i.e., 34–42 years since exposure, and for
whom the period from the first to last measurement was
over 3 years. One patient was excluded because the
blood concentration dropped to one-third the original
level in the first year, and it remained at that concentra-
tion throughout the study period. Table 1 shows the dis-
tribution of the patients by sex and age in 2006, which
was the median of the measurement period.
For each patient, we performed linear regression ana-
lysis with the natural logarithm of 2,3,4,7,8-PeCDF con-
centration in blood lipids as the dependent variable and
the year of measurement as the independent variable,
using the following equation:
lnCit ¼ ki• t þ lnCi0
where Cit is the concentration for patient i and time t,
Ci0 is the concentration for patient i and time 0, and ki
(the slope) is the rate of change in concentration for pa-
tient i.
Ethical approval
The study was approved by the Graduate School of Med-
ical Sciences, Kyushu University (references 25–166), and
the Nara Medical University School of Medicine (reference
281–2).
Results
Figure 1 is a scatter plot of the 2,3,4,7,8-PeCDF concen-
trations and rates of change in concentration. Many pa-
tients with less than 30 pg/g lipid showed increasing
concentrations. This was because the ingestion levels
were comparable with the excretion level, and their con-
centrations were approximately equal to that of the gen-
eral public. Many patients with over 30 pg/g lipid
showed a negative rate of change in concentration,
which signified decreasing concentrations. Although the
differences were not statistically significant, there was a
trend that suggested that the concentration of 2,3,4,7,8-
PeCDF falls more rapidly in those patients with higher
levels of 2,3,4,7,8-PeCDF.
Figure 2 is a scatter plot of the ages and rates of
change of 2,3,4,7,8-PeCDF concentration in patients with
over 50 pg/g lipid. About half women exhibited a posi-
tive rate of change, while most men displayed negative
rates of change. However, many men aged over 80 years
exhibited a positive rate of change in concentration.
From these results, it appears that a change in elimin-
ation may occur around the age of 80 years in men and
50 years in women; however, the number of patients was
too small to confirm this.
Figure 3 shows the distribution of the half-lives in the
different concentration levels of 2,3,4,7,8-PeCDF, com-
paring our previous findings (white bars, [11]) with those
of this study (black bars). Although the calculated half-
lives were variably distributed, we could identify at least
two groups: those with half-lives under 10 years and
those near infinity. In the groups with 2,3,4,7,8-PeCDF
concentrations in blood of >500 pg/g lipid (Fig. 3a) and
200–500 pg/g lipid (Fig. 3b), the proportion of patients
with near infinite half-lives, more than 13.3 years, was
96.9 %, a greater proportion than that seen in our previ-
ous study (78.3 %). In patients with concentrations of
100–200 pg/g lipid (Fig. 3c), we could identify a group
with half-lives of 10.0–13.3 years. In this study, the dis-
tribution of half-lives in most patients whose 2,3,4,7,8-
PeCDF concentrations ranged between 20 and 50 pg/g
lipid (very similar to the general public) appears to be
very much like a normal distribution around the infinite
(Fig. 3e).
Discussion
The concentration of dioxins and dioxin-like com-
pounds in the human body is influenced by the balance
between excretion and ingestion, change in body weight
and measurement error [13, 16]. Current mean blood
concentration of 2,3,4,7,8-PeCDF in the general public is
15.2 pg/g lipid (standard deviation ± 8.9 pg/g lipid) [4].
Among healthy individuals, the current concentration is
the result of ongoing low-level exposure. This likely ex-
plains why Yusho patients with lower 2,3,4,7,8-PeCDF
Table 1 The distribution of the patients by sex and age
Age Male Female Total
20-29 4 0 4
30-39 16 13 29
40-49 18 22 40
50-59 29 36 65
60-69 43 62 105
70-79 56 63 119
80-89 20 12 32
90-99 0 1 1
Total 186 209 395
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concentration had a near normal distribution of half-
lives around the infinite in this study. The half-lives in
patients with higher concentrations than the general
public are less affected by dietary intake of dioxin-
related compounds [2]. For Yusho patients with high
2,3,4,7,8-PeCDF concentrations, such as those in Fig. 3a,
the effects of ingestion were negligible. As has been re-
ported previously [11], the half-lives in patients with
high 2,3,4,7,8-PeCDF concentrations could be divided
into two groups—of around 10 years and near infinity.
Milbrath et al. [13] reported that the concentrations of
dioxins and dioxin-like compounds were influenced by
changes in body weight. However, our previous study
demonstrated that there was no significant relationship
between the long-term rate of change in body weight
and the half-life of 2,3,4,7,8-PeCDF [12]. Other re-
searchers have reported the half-lives of dioxin-like com-
pounds to be under 10–15 years [14], which is partly
consistent with the results of this study; however Ritter
and colleagues studied the general public under the as-
sumption that half-lives were equal in different subject-
s—in other words, that half-lives could be represented
by a single value. Their results were straightforward, but
ignored individual variations. Aylward et al. [1] studied
Fig. 1 Distribution of rate of change by concentration: x-axis, 2,3,4,7,8-PeCDF concentration (pg/g lipid); y-axis, rate of change in concentration of
2,3,4,7,8-PeCDF, calculated by linear regression. The black circles represent men; the white open rhombuses represent women. Solid and dashed
lines are the linear regression plots of men and women, respectively
Fig. 2 Scatter plot of the ages and rates of change in 2,3,4,7,8-PeCDF concentrations in patients with over 50 pg/g lipid. Solid and dashed lines
are the linear regression plots of men and women, respectively. Both lines tend to decrease slowly with increasing age, though the relationship
was not statistically significant
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Fig. 3 Distribution of half-lives at different concentrations of 2,3,4,7,8-PeCDF compared with previously reported half-lives. White bars indicate the
numbers of patients with different half-lives reported by us in 2009 [11]. Black bars indicate the numbers of patients with different half-lives as
calculated in this study. (a) is the distribution of patients who have concentraion of 2,3,4,7,8PeCDF more than 500 pg/g lipid. (b) is the distirubtion
for more than 200 pg/g lipid and less thane 500 pg/g lipid. (c) is the distiribution for more than 100 pg/g lipid and less than 200 pg/g lipid. (d) is
the distribution for more than 50 pg/g lipid and less than 100 pg/g lipid. (e) is then distribution for more than 20 pg/g lipid and less than 50
pg/g lipid
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the half-lives of dioxins in much older people and
found them to be under 15 years; however, the me-
dian body mass index (BMI) of their subjects was
around 32 kg/m2, which is much higher than in our
study (BMI 23 kg/m2); thus, their results may simply
not be applicable to the older Japanese population.
Grandjean et al. [5] reported half-lives for children;
their half-lives were relatively shorter than other reports
for adults. In other words, there appear to be shorter
half-lives in growing children and longer half-lives in
very elderly people. We found that there was a group
with half-lives around 10 years and another group
with half-lives near infinity. The discrepancy between
our results and others might be explained by differ-
ences in the compounds measured, as others have re-
ported the blood concentrations of PCBs and PCDDs,
the pharmacokinetic behaviors of which are known to
be much less extreme than that of 2,3,4,7,8-PeCDF.
However, Flesch-Janys studied the half-lives of PCDDs
and PCDFs [3], there was no difference the half-lives
between PCDDs and PCDFs. The 2,3,4,7,8-PeCDF was
the longest half-life among PCDDs and PCDF which
were evaluated.
One intriguing finding of this study was the existence
of patients with near infinite half-lives of 2,3,4,7,8-
PeCDF. The size of the patient group with half-lives
around 10 years was smaller than that reported in our
previous study [11], whereas the size of the group with
near infinite half-lives became larger. Milbrath et al. [13]
revealed that menopause resulted in rapid changes in
half-lives. Since the subjects in the present study com-
prised mainly older men and women, menstruation sta-
tus would not have influenced our results. We have
reported that one factor affecting dioxin half-lives is the
excretion of dioxin-containing sebum through the skin
[12]; this is in accordance with previous findings
whereby sebum is an important human excretion path-
way [7, 17]. If the excretion of sebum through the skin is
decreased by aging, the excretion of dioxins through the
skin would likewise diminish.
Conclusions
The half-lives of 2,3,4,7,8-PeCDF varied among Yusho
patients. The half-lives in patients with high 2,3,4,7,8-
PeCDF concentrations could be divided into two group-
s—those of around 10 years, and those near infinity. The
former group became smaller in number over time,
whereas the latter became larger. The increased number
of patients with near infinite half-lives would appear to
be explained by age-related factors.
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